JP6573286B2 - 感染の処置での使用のための治療剤 - Google Patents
感染の処置での使用のための治療剤 Download PDFInfo
- Publication number
- JP6573286B2 JP6573286B2 JP2017503081A JP2017503081A JP6573286B2 JP 6573286 B2 JP6573286 B2 JP 6573286B2 JP 2017503081 A JP2017503081 A JP 2017503081A JP 2017503081 A JP2017503081 A JP 2017503081A JP 6573286 B2 JP6573286 B2 JP 6573286B2
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- carrier
- donor
- acetyl
- micro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
(リストA)
過ホウ酸ナトリウム
過炭酸ナトリウム
過リン酸ナトリウム
過酸化尿素
パーエステル
スーパーオキシド
ジオキシゲニル
オゾン
過酸化水素
過酸化リチウム
過酸化バリウム
ジ−tert−過酸化ブチル
パーオキシ二硫酸アンモニウム
パーオキシ一硫酸カリウム。
リストAからの過炭酸ナトリウム、過炭酸カリウム、過炭酸アンモニウム、過ホウ酸ナトリウム、過ホウ酸アンモニウム、過硫酸アンモニウムおよび過酸化尿素の何れかまたは組み合わせが特に好ましい。
(リストB)
テトラアセチルエチレンジアミン(TAED)
メチルセルロース封入TAEDまたは封入供与体
アセチルサリチル酸
ジアセチルジオキソヘキサヒドラトリアジン(diacetyl dioxohexahydratriazine)(DADHT)
テトラアセチルグリコルリル
アセチル尿素
ジ−アセチル尿素
トリ−アセチル尿素
ペンタアセチルグルコース(PAG)
テトラアセチルグリコルリル(TAGU)
アセチルホスフェート
アセチルイミダゾール
アセチルCoA
無水酢酸
ヘミアセタール基を含有する化合物
酢酸
ジ−,アセチルモルフィン
ピルベート
アセチルクロリド
アセチル−カプロラクタム
N’N’−ジアセチル−N’N’−ジメチル尿素。
アセチル供与体としてのテトラアセチルエチレンジアミン(TAED)の使用が特に好ましい。
1.10%の過炭酸ナトリウムが担持された、直径が200x10−3μmの乳酸グリコール酸共重合体(PLGA)に基づくナノ粒子担体。
2.80%の担持効率まで過炭酸ナトリウムが担持された、直径が20x10−3μm〜100x10−3μm(境界値を含む)の範囲の乳酸グリコール酸共重合体(PLGA)に基づくナノ粒子担体。
3.単独で、または0.1%〜50%の担持効率まで過炭酸ナトリウムおよびテトラアセチルエチレンジアミンと組み合わせて担持される乳酸グリコール酸共重合体(PLGA)に基づくナノ粒子担体。
4.単独で、または65%の合わせた担持効率まで過硫酸ナトリウムおよびアセチルサリチル酸と組み合わせて担持されるポリエチレンイミン(PEI)担体。
5.75%の担持効率まで過酸化尿素が担持された、直径が100μm〜1000μm(境界値を含む)の範囲である乳酸グリコール酸共重合体(PLGA)に基づくナノ粒子担体。
6.40%の担持効率の、粒子の直径が20x10−3μm〜300x10−3μm(境界値を含む)の範囲である、過炭酸ナトリウムが担持されたPEG付加ナノ粒子担体。
7.50%〜80%(境界値を含む)の担持効率まで過炭酸ナトリウムが担持された、直径がおよそ300μmである乳酸グリコール酸共重合体(PLGA)に基づくマイクロ粒子担体。
8.過炭酸とTAEDとの比がおよそ2:1である、テトラアセチルエチレンジアミンを担持されたPLGA粒子と混合して過炭酸ナトリウムが担持された、キトサンに基づくナノ粒子。
Claims (15)
- ヒトまたは動物の感染の処置での使用のためのナノまたはマイクロスケールの治療剤であって、マイクロおよび/またはナノ粒子担体を含み、
前記担体は、過酸素供与体およびアセチル供与体を含む不活性前駆化学物質を、単一でまたは1つ以上組み合わせて担持しており、
前記担体が、感染部位での曝露後に生理的環境により活性化されて前記過酸素供与体が過酸化水素を形成させ、前記アセチル供与体が前記過酸化水素と反応して、過酢酸と過酸化水素との混合物を生成させるようになる前記前駆化学物質(1つまたは複数)を封入し、
前記粒子担体が、熱誘導性相分離および凍結乾燥によって前記前駆化学物質が組み込まれた生分解性ポリマーから構成される、
ナノまたはマイクロスケールの治療剤。 - 前記過酸素供与体が、次のような化学物質:過ホウ酸ナトリウム、過炭酸ナトリウム、過リン酸ナトリウム、過酸化尿素、パーエステル、スーパーオキシド、ジオキシゲニル、オゾン、過酸化水素、過酸化リチウム、過酸化バリウム、ジ−tert−過酸化ブチル、パーオキシ二硫酸アンモニウム、パーオキシ一硫酸カリウムの何れかまたは何れかの組み合わせである、請求項1に記載の治療剤。
- 前記過酸素供与体が、過炭酸ナトリウム、過炭酸カリウム、過炭酸アンモニウム、過ホウ酸ナトリウム、過ホウ酸アンモニウム、過硫酸アンモニウムおよび過酸化尿素の何れかまたは組み合わせである、請求項1に記載の治療剤。
- 前記アセチル供与体が、次のリスト中の化学物質:テトラアセチルエチレンジアミン(TAED)、メチルセルロース封入TAEDまたは封入供与体、アセチルサリチル酸、ジアセチルジオキソヘキサヒドラトリアジン(diacetyl dioxohexahydratriazine)(DADHT)、テトラアセチルグリコルリル、アセチル尿素、ジアセチル尿素、トリアセチル尿素、ペンタアセチルグルコース(PAG)、テトラアセチルグリコルリル(TAGU)、アセチルホスフェート、アセチルイミダゾール、アセチルCoA、無水酢酸、ヘミアセタール基を含有する化合物、酢酸、ジ−,アセチルモルフィン、ピルベート、アセチルクロリド、アセチル−カプロラクタム、N’N’−ジアセチル−N’N’−ジメチル尿素の何れかまたは何れかの組み合わせである、請求項1に記載の治療剤。
- 前記アセチル供与体がテトラアセチルエチレンジアミン(TAED)を含む、請求項6または請求項1に記載の治療剤。
- 前記マイクロおよび/またはナノ粒子担体の少なくとも一部がそれぞれ過酸素供与体およびアセチル供与体を封入する、請求項1から5の何れかに記載の治療剤。
- 前記過酸素供与体(1つまたは複数)または前記アセチル供与体(1つまたは複数)の何れかを個々に封入するマイクロおよび/またはナノ粒子担体の組み合わせを含む、請求項1から6の何れかに記載の治療剤。
- 前記前駆化学物質(1つまたは複数)の放出が、前記感染部位でインシトゥで前記担体が破裂するか、分解するか、またはその空隙率が変化したときに起こる、請求項1から7の何れかに記載の治療剤。
- 前記担体が、経時的に加水分解を介して分解して、前記前駆化学物質(1つまたは複数)の制御放出をもたらす、請求項8に記載の治療剤。
- 前記生分解性ポリマーが、デンドリマー、バッキーボール、メソ孔シリカおよびナノカーボンチューブの何れかまたは混合物である、請求項1から9の何れかに記載の治療剤。
- 前記マイクロおよび/またはナノ粒子担体が、ミセル、リポソームおよびエトソームの何れかまたは混合物である、請求項1から9の何れかに記載の治療剤。
- 前記担体が乳酸グリコール酸共重合体(PLGA)から構成される、請求項1から11の何れかに記載の治療剤。
- 前記担体がPEG付加されている、請求項1から12の何れかに記載の治療剤。
- 前記担体が標的化リガンドで処理されている、請求項1から13の何れかに記載の治療剤。
- 前記担体が、バイオセンサーによって標的化される、請求項1から14の何れかに記載の治療剤。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1405874.7A GB201405874D0 (en) | 2014-04-01 | 2014-04-01 | A therapeutic agent for use in the treatment of infections |
GB1405874.7 | 2014-04-01 | ||
GBGB1415063.5A GB201415063D0 (en) | 2014-04-01 | 2014-08-26 | A therapeutic agent for use in the treatment of infections |
GB1415063.5 | 2014-08-26 | ||
PCT/GB2015/000100 WO2015150722A1 (en) | 2014-04-01 | 2015-03-24 | A therapeutic agent for use in the treatment of infections |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017510648A JP2017510648A (ja) | 2017-04-13 |
JP2017510648A5 JP2017510648A5 (ja) | 2019-06-20 |
JP6573286B2 true JP6573286B2 (ja) | 2019-09-11 |
Family
ID=50737835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017503081A Active JP6573286B2 (ja) | 2014-04-01 | 2015-03-24 | 感染の処置での使用のための治療剤 |
Country Status (16)
Country | Link |
---|---|
US (2) | US9913805B2 (ja) |
EP (2) | EP3848022B1 (ja) |
JP (1) | JP6573286B2 (ja) |
KR (2) | KR102482597B1 (ja) |
CN (1) | CN106456557B (ja) |
AU (1) | AU2015242495B2 (ja) |
CA (1) | CA2943431C (ja) |
DK (1) | DK3125874T3 (ja) |
ES (2) | ES2855985T3 (ja) |
GB (3) | GB201405874D0 (ja) |
IL (1) | IL247969B (ja) |
MX (1) | MX2016012757A (ja) |
NZ (1) | NZ724298A (ja) |
SG (2) | SG11201608093WA (ja) |
WO (1) | WO2015150722A1 (ja) |
ZA (1) | ZA201606387B (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201405874D0 (en) * | 2014-04-01 | 2014-05-14 | Aga Nanotech Ltd | A therapeutic agent for use in the treatment of infections |
CN107281220B (zh) * | 2016-03-31 | 2020-02-14 | 中国科学院上海硅酸盐研究所 | 一种介孔氧化硅基活性氧(ros)放疗增敏剂及其制备方法 |
CN106860032B (zh) * | 2016-10-25 | 2021-04-09 | 咏达生医材料股份有限公司 | 一种气态皮肤供氧美白产品及其应用 |
JP2019194162A (ja) * | 2018-05-01 | 2019-11-07 | ツァ ギャリー | 肌の酸素供給による美白及び加熱機能を備えた通気性材料 |
GB2592911B (en) | 2020-02-28 | 2023-06-28 | Aga Nanotech Ltd | A plasma-activatable wound dressing for treatment of infections |
GB202005556D0 (en) | 2020-04-16 | 2020-06-03 | Aga Nanotech Ltd | Covid face mask |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997007777A1 (en) * | 1995-08-15 | 1997-03-06 | Robert Eric Montgomery | Peroxidase-activating oral compositions |
ATE304343T1 (de) * | 1999-07-02 | 2005-09-15 | Cognis Ip Man Gmbh | Mikrokapseln - iv |
AU4477001A (en) * | 2000-04-18 | 2001-10-30 | Peptron Inc. | Injectable sustained release pharmaceutical composition and processes for preparing the same |
KR100342746B1 (ko) * | 2000-06-27 | 2002-07-03 | 김찬화 | 인슐린의 방출제어제제 및 그 방법 |
GB0411304D0 (en) * | 2004-05-21 | 2004-06-23 | Fellows Adrian N | An antimicrobial composition |
US20060088498A1 (en) * | 2004-10-27 | 2006-04-27 | Truox, Inc. | Anti-microbial composition using in-situ generation of an oxidizing agent |
CA2617869C (en) * | 2005-08-04 | 2017-02-14 | Thomas William Rademacher | Nanoparticles comprising antibacterial ligands |
KR20070071225A (ko) * | 2005-12-29 | 2007-07-04 | 애경산업(주) | 치아 미백용 조성물 |
GB0711952D0 (en) | 2007-06-20 | 2007-08-01 | King S College London | Microspheres |
WO2009108407A1 (en) * | 2008-02-25 | 2009-09-03 | The University Of North Carolina At Charlotte Office Of Technology Transfer | Biodegradable therapeutic nanoparticles containing an antimicrobial agent |
AU2009270849B2 (en) * | 2008-07-17 | 2013-11-21 | Micell Technologies, Inc. | Drug delivery medical device |
US8969282B2 (en) * | 2009-02-05 | 2015-03-03 | American Sterilizer Company | Low odor, hard surface sporicide |
JP5960593B2 (ja) | 2009-04-27 | 2016-08-02 | プレミア デンタル プロダクツ カンパニー | マイクロカプセル化組成物及び組織石灰化の方法 |
KR101136028B1 (ko) * | 2009-04-27 | 2012-04-18 | 한양대학교 산학협력단 | 다공성 마이크로스피어의 제조방법 |
NZ600269A (en) * | 2009-05-20 | 2014-02-28 | Dec Int Nz Ltd | Delivery device for treatment of mastitis |
US9187594B2 (en) * | 2010-02-09 | 2015-11-17 | The Regents Of The University Of Michigan | Nano-fibrous microspheres and methods for making the same |
CA2804601C (en) * | 2010-07-09 | 2020-05-19 | Innocore Technologies B.V. | Biodegradable phase separated segmented multi block co-polymers and release of biologically active polypeptides |
CA2812063A1 (en) * | 2010-08-30 | 2012-06-07 | President And Fellows Of Harvard College | Shear controlled release for stenotic lesions and thrombolytic therapies |
GB201405874D0 (en) * | 2014-04-01 | 2014-05-14 | Aga Nanotech Ltd | A therapeutic agent for use in the treatment of infections |
-
2014
- 2014-04-01 GB GBGB1405874.7A patent/GB201405874D0/en not_active Ceased
- 2014-08-26 GB GBGB1415063.5A patent/GB201415063D0/en not_active Ceased
-
2015
- 2015-03-24 EP EP20215977.8A patent/EP3848022B1/en active Active
- 2015-03-24 EP EP15714598.8A patent/EP3125874B1/en active Active
- 2015-03-24 SG SG11201608093WA patent/SG11201608093WA/en unknown
- 2015-03-24 KR KR1020227003691A patent/KR102482597B1/ko active IP Right Grant
- 2015-03-24 ES ES15714598T patent/ES2855985T3/es active Active
- 2015-03-24 NZ NZ724298A patent/NZ724298A/en unknown
- 2015-03-24 MX MX2016012757A patent/MX2016012757A/es active IP Right Grant
- 2015-03-24 ES ES20215977T patent/ES2953755T3/es active Active
- 2015-03-24 JP JP2017503081A patent/JP6573286B2/ja active Active
- 2015-03-24 WO PCT/GB2015/000100 patent/WO2015150722A1/en active Application Filing
- 2015-03-24 CN CN201580018976.4A patent/CN106456557B/zh active Active
- 2015-03-24 US US15/126,511 patent/US9913805B2/en active Active
- 2015-03-24 CA CA2943431A patent/CA2943431C/en active Active
- 2015-03-24 SG SG10201801524PA patent/SG10201801524PA/en unknown
- 2015-03-24 GB GB1617053.2A patent/GB2538923B/en active Active
- 2015-03-24 AU AU2015242495A patent/AU2015242495B2/en active Active
- 2015-03-24 KR KR1020167030614A patent/KR102359855B1/ko active IP Right Grant
- 2015-03-24 DK DK15714598.8T patent/DK3125874T3/da active
-
2016
- 2016-09-15 ZA ZA2016/06387A patent/ZA201606387B/en unknown
- 2016-09-22 IL IL247969A patent/IL247969B/en active IP Right Grant
-
2018
- 2018-01-18 US US15/874,552 patent/US10933026B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6573286B2 (ja) | 感染の処置での使用のための治療剤 | |
Liang et al. | Facile synthesis of ZnO QDs@ GO-CS hydrogel for synergetic antibacterial applications and enhanced wound healing | |
Su et al. | Biofilms: formation, research models, potential targets, and methods for prevention and treatment | |
Smith | Biofilms and antibiotic therapy: is there a role for combating bacterial resistance by the use of novel drug delivery systems? | |
AU2015315108B2 (en) | Antimicrobial and biologically active polymer composites and related methods, materials and devices | |
Li et al. | Biguanide-derived polymeric nanoparticles kill MRSA biofilm and suppress infection in vivo | |
CN107441488A (zh) | 一种黑磷量子点复合材料及其制备方法和应用 | |
Shevchenko et al. | Antimicrobial effect of biocompatible silicon nanoparticles activated using therapeutic ultrasound | |
Bai et al. | Synergistic photothermal antibacterial therapy enabled by multifunctional nanomaterials: Progress and perspectives | |
Quijia et al. | Metal-organic frameworks for diagnosis and therapy of infectious diseases | |
Shende et al. | Polymeric nanodroplets: an emerging trend in gaseous delivery system | |
Altun et al. | Metal-based nanoparticles for combating antibiotic resistance | |
JP2017510648A5 (ja) | ||
Li et al. | Nano–Bio Interactions: Biofilm‐Targeted Antibacterial Nanomaterials | |
Kanth et al. | Recent advancements and perspective of ciprofloxacin-based antimicrobial polymers | |
CN213687182U (zh) | 一种空气净化装置 | |
JP5397726B2 (ja) | カーボンナノホーンをキャリアとする抗菌剤徐放化製剤 | |
US20190060270A1 (en) | Disinfectant agent | |
JP2023516026A (ja) | 活性化可能な創傷被覆材 | |
Stewart | Co-Assembled Drug-Silica Materials for Antimicrobial and Antidegradative Dental Applications | |
CN108552169A (zh) | 一种缓释高效聚γ-谷氨酸/十二烷基二甲基苄基氯化铵纳米杀菌剂及其制备方法、应用 | |
BR112012007111B1 (pt) | Composição microbicida para revestimento de um dispositivo médico, dispositivo médico e método para fabricação de um revestimento para um dispositivo médico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161201 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181018 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181019 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190117 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190228 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20190516 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190709 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190807 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6573286 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |